Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

Published:2020-06 Issue:10240 Volume:395 Page:1835-1844
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Gutzmer Ralf,Stroyakovskiy Daniil,Gogas Helen,Robert Caroline,Lewis Karl,Protsenko Svetlana,Pereira Rodrigo P,Eigentler Thomas,Rutkowski Piotr,Demidov Lev,Manikhas Georgy Moiseevich,Yan Yibing,Huang Kuan-Chieh,Uyei Anne,McNally Virginia,McArthur Grant A,Ascierto Paolo A

Publisher

Elsevier BV

Subject

General Medicine

Reference29 articles.

1. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

2. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma;Larkin;N Engl J Med,2014

3. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med,2015

4. Improved overall survival in melanoma with combined dabrafenib and trametinib;Robert;N Engl J Med,2015

5. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med,2015

Cited by 488 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Therapy Innovations for Melanoma;Hematology/Oncology Clinics of North America;2024-10

2. Neoadjuvant therapy for melanoma: past, present, and future;Surgical Oncology;2024-10

3. Progress in Immune Checkpoint Inhibitor for Melanoma Therapy;Hematology/Oncology Clinics of North America;2024-10

4. Advances in Adjuvant and Neoadjuvant Therapy for Melanoma;Hematology/Oncology Clinics of North America;2024-10

5. A phase 1b study of the ERK inhibitor MK-8353 plus pembrolizumab in patients with advanced solid tumors;Investigational New Drugs;2024-09-14